Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

28.89USD
20 Aug 2014
Price Change (% chg)

$-0.05 (-0.17%)
Prev Close
$28.94
Open
$28.81
Day's High
$28.98
Day's Low
$28.75
Volume
3,201,828
Avg. Vol
5,764,736
52-wk High
$32.96
52-wk Low
$27.76

PFE.N

Chart for PFE.N

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.68
Market Cap (Mil.): $183,187.50
Shares Outstanding (Mil.): 6,340.86
Dividend: 0.26
Yield (%): 3.60

Financials

  PFE.N Industry Sector
P/E (TTM): 18.22 32.90 33.74
EPS (TTM): 1.59 -- --
ROI: 6.80 18.79 18.03
ROE: 13.38 19.42 18.77
Search Stocks

U.S. advisory panel recommends Prevnar 13 vaccine for elderly

- An influential U.S. medical advisory panel on Wednesday recommended that people 65 and older be given Pfizer Inc's blockbuster Prevnar 13 vaccine to protect against pneumococcal bacteria that can cause pneumonia and other infections.

13 Aug 2014

U.S. advisory panel recommends Prevnar 13 vaccine for elderly

Aug 13 - An influential U.S. medical advisory panel on Wednesday recommended that people 65 and older be given Pfizer Inc's blockbuster Prevnar 13 vaccine to protect against pneumococcal bacteria that can cause pneumonia and other infections.

13 Aug 2014

UPDATE 1-AstraZeneca gets pipeline boost from good gout drug results

LONDON, Aug 13 - AstraZeneca, which fended off a $118 billion takeover approach from Pfizer in May, reported positive results for an experimental gout drug on Wednesday that could boost its sales modestly.

13 Aug 2014

Pfizer to help 23andMe unravel genetic ties to bowel disease

Aug 12 - Home genetics company 23andMe on Tuesday said it hopes to uncover gene mutations linked to inflammatory bowel disease (IBD) by enrolling 10,000 people with the hard-to-treat malady and examining DNA from their donated saliva samples.

12 Aug 2014

Pfizer to help 23andMe unravel genetic ties to bowel disease

- Home genetics company 23andMe on Tuesday said it hopes to uncover gene mutations linked to inflammatory bowel disease (IBD) by enrolling 10,000 people with the hard-to-treat malady and examining DNA from their donated saliva samples.

12 Aug 2014

INSIGHT-Pfizer confronts surge of lawsuits over Lipitor

Aug 8 - Pharmaceutical giant Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public.

08 Aug 2014

Pfizer confronts surge of lawsuits over Lipitor

- Pharmaceutical giant Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public.

08 Aug 2014

INSIGHT-Pfizer confronts surge of lawsuits over Lipitor

Aug 8 - Pharmaceutical giant Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public.

08 Aug 2014

Pfizer to pay $35 million to U.S. states to settle Rapamune claims

NEW YORK - Pfizer Inc agreed to pay $35 million to 41 U.S. states and Washington, D.C. to settle claims that its Wyeth unit illegally marketed the drug Rapamune, and encouraged doctors and hospitals to prescribe it for off-label uses.

06 Aug 2014

Pfizer to pay $35 mln to U.S. states to settle Rapamune claims

NEW YORK, Aug 6 - Pfizer Inc agreed to pay $35 million to 41 U.S. states and Washington, D.C. to settle claims that its Wyeth unit illegally marketed the drug Rapamune, and encouraged doctors and hospitals to prescribe it for off-label uses.

06 Aug 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.21 +0.25
Novartis AG (NOVN.VX) CHF81.05 +0.20
Merck & Co., Inc. (MRK.N) $59.48 +0.57
Roche Holding Ltd. (ROG.VX) CHF266.20 +0.70
Abbott Laboratories (ABT.N) $42.14 -0.40
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €80.17 +0.89
AstraZeneca plc (AZN.L) 4,377.00p +92.00
GlaxoSmithKline plc (GSK.L) 1,441.00p +23.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks